Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation
暂无分享,去创建一个
J. Mellors | R. Bosch | C. Rinaldo | A. Collier | S. Riddler | J. Eron | R. Gandhi | C. Godfrey | E. Hogg | D. McMahon | Christina M Lalama | J. Cyktor | B. Macatangay | C. Lalama
[1] F. Palella,et al. Suboptimal Adherence to Combination Antiretroviral Therapy Is Associated With Higher Levels of Inflammation Despite HIV Suppression. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] S. Gianella,et al. Cytomegalovirus and HIV: A Dangerous Pas de Deux. , 2016, The Journal of infectious diseases.
[3] R. Dewar,et al. Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy , 2016, Proceedings of the National Academy of Sciences.
[4] Richard Jefferys,et al. International AIDS Society global scientific strategy: towards an HIV cure 2016 , 2016, Nature Medicine.
[5] G. Pantaleo,et al. PD-1+ and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals , 2016, Nature Medicine.
[6] Steven G. Deeks,et al. Persistent HIV-1 replication during antiretroviral therapy , 2016, Current opinion in HIV and AIDS.
[7] F. Vaida,et al. Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy. , 2016, The Journal of infectious diseases.
[8] J. Mellors,et al. Novel Assays for Measurement of Total Cell-Associated HIV-1 DNA and RNA , 2016, Journal of Clinical Microbiology.
[9] M. Lederman,et al. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption , 2015, AIDS.
[10] Nancie M Archin,et al. Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies. , 2015, The Journal of infectious diseases.
[11] C. Charpentier,et al. Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy , 2015, AIDS.
[12] M. Lederman,et al. Differential Reduction in Monocyte Activation and Vascular Inflammation With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among HIV-Infected Individuals. , 2015, The Journal of infectious diseases.
[13] R. Siliciano,et al. Towards an HIV-1 cure: measuring the latent reservoir. , 2015, Trends in microbiology.
[14] J. Mellors,et al. HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] R. Siliciano,et al. CD4+ and CD8+ T Cell Activation Are Associated with HIV DNA in Resting CD4+ T Cells , 2014, PloS one.
[16] John W. Mellors,et al. Improved Single-Copy Assays for Quantification of Persistent HIV-1 Viremia in Patients on Suppressive Antiretroviral Therapy , 2014, Journal of Clinical Microbiology.
[17] S. Deeks,et al. Immunologic strategies for HIV-1 remission and eradication , 2014, Science.
[18] Jinyan Liu,et al. Rapid Seeding of the Viral Reservoir Prior to SIV Viremia in Rhesus Monkeys , 2014, Nature.
[19] M. Lederman,et al. HIV-Infected Individuals with Low CD4/CD8 Ratio despite Effective Antiretroviral Therapy Exhibit Altered T Cell Subsets, Heightened CD8+ T Cell Activation, and Increased Risk of Non-AIDS Morbidity and Mortality , 2014, PLoS pathogens.
[20] E. Rosenberg,et al. HIV-1 persistence in CD4+ T cells with stem cell-like properties , 2014, Nature Medicine.
[21] D. Douek,et al. Systemic effects of inflammation on health during chronic HIV infection. , 2013, Immunity.
[22] C. Tamalet,et al. Lack of correlation between the size of HIV proviral DNA reservoir and the level of immune activation in HIV-infected patients with a sustained undetectable HIV viral load for 10 years. , 2013, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[23] Jeffrey N. Martin,et al. Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. , 2013, The Journal of infectious diseases.
[24] D. Douek,et al. Immune activation and HIV persistence: implications for curative approaches to HIV infection , 2013, Immunological reviews.
[25] R. Siliciano,et al. Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies , 2013, PLoS pathogens.
[26] A. Perelson,et al. Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection , 2012, Proceedings of the National Academy of Sciences.
[27] S. Kreth,et al. Selection of reliable reference genes for quantitative real-time PCR in human T cells and neutrophils , 2011, BMC Research Notes.
[28] Handan Wand,et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. , 2011, The Journal of infectious diseases.
[29] P. Hogendoorn,et al. Opening the archives for state of the art tumour genetic research: sample processing for array-CGH using decalcified, formalin-fixed, paraffin-embedded tissue-derived DNA samples , 2011, BMC Research Notes.
[30] M. Lederman,et al. The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial , 2010, PLoS medicine.
[31] Geneviève Boucher,et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation , 2009, Nature Medicine.
[32] Lewis H Kuller,et al. Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection , 2008, PLoS medicine.
[33] R. Bosch,et al. AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT): Rationale, Design, and Baseline Characteristics , 2008, HIV clinical trials.
[34] A. Haase,et al. The role of collagen deposition in depleting CD4+ T cells and limiting reconstitution in HIV-1 and SIV infections through damage to the secondary lymphoid organ niche. , 2008, Seminars in immunology.
[35] J. Mellors,et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy , 2008, Proceedings of the National Academy of Sciences.
[36] R. Haubrich,et al. Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. , 2008, The Journal of infectious diseases.
[37] Joseph A Kovacs,et al. ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy Viremia , 2007, PLoS pathogens.
[38] J. Brenchley,et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection , 2006, Retrovirology.
[39] Matthew C Strain,et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. , 2005, The Journal of infectious diseases.
[40] R. Siliciano,et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells , 2003, Nature Medicine.
[41] Jeffrey N. Martin,et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. , 2003, The Journal of infectious diseases.
[42] R. Greenblatt,et al. Erratum: Does patient sex affect human immunodeficiency virus levels? (Clinical Infectious Diseases (2002) 35 (313-322)) , 2002 .
[43] R. Greenblatt,et al. Does patient sex affect human immunodeficiency virus levels? , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[44] R. Lempicki,et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[45] B. Clotet,et al. Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients. , 1999, AIDS.
[46] G. Salama,et al. Decay of HIV-1 DNA in patients receiving suppressive antiretroviral therapy. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[47] M A Nowak,et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[48] R Brookmeyer,et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.
[49] D. Richman,et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.